The estimated Net Worth of Kaitlin M. Kestenberg Messina is at least $8 millió dollars as of 30 August 2024. Kaitlin Messina owns over 24,150 units of Adma Biologics Inc stock worth over $8,002,455 and over the last few years Kaitlin sold ADMA stock worth over $0.
Kaitlin has made over 1 trades of the Adma Biologics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Kaitlin exercised 24,150 units of ADMA stock worth $93,461 on 30 August 2024.
The largest trade Kaitlin's ever made was exercising 24,150 units of Adma Biologics Inc stock on 30 August 2024 worth over $93,461. On average, Kaitlin trades about 6,038 units every 0 days since 2024. As of 30 August 2024 Kaitlin still owns at least 473,238 units of Adma Biologics Inc stock.
You can see the complete history of Kaitlin Messina stock trades at the bottom of the page.
Kaitlin's mailing address filed with the SEC is C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW,, BOCA RATON, FL, 33487.
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... és Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
Adma Biologics Inc executives and other stock owners filed with the SEC include: